Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2010 - 2026)
Rigel Pharmaceuticals (RIGL) recorded quarterly Depreciation & Amortization (CF) of $597000.0 in Q1 2026, down 0.67% quarter-over-quarter from $601000.0 in Q4 2025, and down 1.16% on a YoY basis from $604000.0 in Q1 2025.
Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $597000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 1.16% year-over-year to $597000.0; the TTM figure through Mar 2026 stood at $2.4 million (down 0.99% YoY), while the FY2025 annual figure was $2.4 million, up 8.39% from the prior year.
- Depreciation & Amortization (CF) was $597000.0 for Q1 2026 at Rigel Pharmaceuticals, down from $601000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $613000.0 in Q2 2024 to a low of $237000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $439764.7 across 5 years, with a median of $400000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) decreased 29.7% in 2022, then surged 109.25% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $284000.0 in 2022, then rose by 3.17% to $293000.0 in 2023, then soared by 106.14% to $604000.0 in 2024, then dropped by 0.5% to $601000.0 in 2025, then decreased by 0.67% to $597000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $597000.0 (Q1 2026), $601000.0 (Q4 2025), and $603000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Rigel Pharmaceuticals | 603.18 Mn | 456.49 Mn | 54.21 Mn | 597,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 597,000.00 |
| Mar 31, 2026 | 597,000.00 |
| Dec 31, 2025 | 601,000.00 |
| Dec 31, 2025 | 601,000.00 |
| Sep 30, 2025 | 603,000.00 |
| Sep 30, 2025 | 603,000.00 |
| Jun 30, 2025 | 607,000.00 |
| Jun 30, 2025 | 607,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Dec 31, 2024 | 604,000.00 |
| Dec 31, 2024 | 604,000.00 |
| Sep 30, 2024 | 611,000.00 |
| Sep 30, 2024 | 611,000.00 |
| Jun 30, 2024 | 613,000.00 |
| Jun 30, 2024 | 613,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 293,000.00 |
| Dec 31, 2023 | 293,000.00 |